Cabaletta Bio to Present at the Cowen and Company 40th Annual Health Care Conference

PHILADELPHIA, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. CABA, a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer and Co-founder, will present at the Cowen and Company 40th Annual Health Care Conference on Tuesday, March 3, 2020, at 10:40 a.m. EST. The conference will be held at the Boston Marriott Copley Place in Boston, Massachusetts. 

A live audio webcast of the presentation can be accessed through the Events & Presentations section of the Company's website at investors.cabalettabio.com. An archived replay of the webcast will be available on the Company's website for approximately 90 days following the live presentation.

About Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA) platform, in combination with Cabaletta's proprietary technology, utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company's lead product candidate is being studied in a Phase 1 clinical trial as a potential treatment for a prototypical B cell-mediated autoimmune disease, mucosal pemphigus vulgaris. For more information, visit www.cabalettabio.com.

Investors and Contacts:

Anup Marda

Chief Financial Officer

investors@cabalettabio.com

Media:

Ryo Imai / Robert Flamm, Ph.D.

212-213-0006, ext. 315 / ext. 364

rimai@burnsmc.com / rflamm@burnsmc.com